Bevacizumab in the treatment of metastatic breast cancer: Friend or foe?

Current Oncology Reports

Volumn 14, Issue 1, 2012, Pages 1-11

  Montero, Alberto J ^a   Escobar, Mauricio ^a   Lopes, Gilberto ^b   Glück, Stefan ^a   Vogel, Charles ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anti angiogenesis; Bevacizumab; Chemotherapy; Metastatic breast cancer; Randomized control (phase 3) trials; Review

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; ERIBULIN; MOTESANIB; NAVELBINE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INFECTION; INTESTINE PERFORATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NONHUMAN; PROTEINURIA; SENSORY NEUROPATHY; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 84857626952     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0202-z     Document Type: Article

References (51)

1. MA Cobleigh VK Langmuir GW Sledge KD Miller L Haney WF Novotny, et al. 2003 A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 5 Suppl 16 117 24 14613032 10.1053/j.seminoncol.2003.08.013 1:CAS:528:DC%2BD3sXhtVSjtrvF (Pubitemid 37433402)
2. MH Cohen J Gootenberg P Keegan R Pazdur 2007 FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer Oncologist 12 3 356 61 17405901 10.1634/theoncologist.12-3-356 1:CAS:528:DC%2BD2sXlsVSqur8%3D (Pubitemid 46556802)
3. MH Cohen J Gootenberg P Keegan R Pazdur 2007 FDA drug approval summary: bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer Oncologist 12 6 713 8 17602060 10.1634/theoncologist.12-6-713 1:CAS:528: DC%2BD2sXosF2gsLw%3D (Pubitemid 47036205)
4. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 7070 932 6 16355210 10.1038/nature04478 1:CAS:528:DC%2BD2MXhtlSksrjF (Pubitemid 43093958)
5. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 10 795 803 12360282 10.1038/nrc909 1:CAS:528:DC%2BD38XnsVGrtbk%3D (Pubitemid 37328914)
6. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1182 6 4938153 10.1056/NEJM197111182852108 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
7. G Korpanty LA Sullivan E Smyth DN Carney RA Brekken 2010 Molecular and clinical aspects of targeting the VEGF pathway in tumors J Oncol. 2010 652320 20628530
8. GD Yancopoulos S Davis NW Gale JS Rudge SJ Wiegand J Holash 2000 Vascular-specific growth factors and blood vessel formation Nature 407 6801 242 8 11001067 10.1038/35025215 1:CAS:528:DC%2BD3cXmvVSlsrY%3D
9. DW Leung G Cachianes WJ Kuang DV Goeddel N Ferrara 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 4935 1306 9 2479986 10.1126/science.2479986 1:CAS:528:DyaK3cXls1GltLo%3D (Pubitemid 20066716)
10. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 6 669 76 12778165 10.1038/nm0603-669 1:CAS:528:DC%2BD3sXktFOnur4%3D (Pubitemid 36749215)
11. K Holmes OL Roberts AM Thomas MJ Cross 2007 Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition Cell Signal 19 10 2003 12 17658244 10.1016/j.cellsig.2007.05.013 1:CAS:528:DC%2BD2sXovFylsLs%3D (Pubitemid 47354167)
12. N Ferrara 2004 Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 4 581 611 15294883 10.1210/er.2003-0027 1:CAS:528:DC%2BD2cXns1Ght74%3D (Pubitemid 39099316)
13. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 9 987 9 11533692 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D (Pubitemid 32937367)
14. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 5706 58 62 15637262 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar (Pubitemid 40093472)
15. DG Duda RK Jain CG Willett 2007 Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers J Clin Oncol 25 26 4033 42 17827451 10.1200/JCO.2007.11.3985 1:CAS:528:DC%2BD2sXhtlKqsb3E (Pubitemid 47492947)
16. N Ferrara KJ Hillan HP Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 391 400 15136787 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D (Pubitemid 38618122)
17. R Gray S Bhattacharya C Bowden K Miller RL Comis 2009 Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer J Clin Oncol 27 30 4966 72 19720913 10.1200/JCO.2008.21.6630 1:CAS:528:DC%2BD1MXhsVCrsr%2FJ
18. M Martin H Roche T Pinter J Crown MJ Kennedy L Provencher, et al. 2011 Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol 12 4 369 76 21429799 10.1016/S1470-2045(11)70037-7 1:CAS:528: DC%2BC3MXkt1Gqsrc%3D This study showed that weekly paclitaxel plus bevacizumab had a median PFS of 11.5 months which was almost identical to that seen in E2100, versus 9.0 for paclitaxel, which was better than what was observed in the control arm in E2100. This study also showed that the oral anti-angiogenic agent motesanib when combined with paclitaxel was no better than placebo
19. Ito Y, Aogi K, Masuda N, Ohno S, Oda T, Iwata H, et al. Efficacy of first-line bevacizumab (bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): results of a japanese phase II study (n∈=∈120). J Clin Oncol. 2011;29(suppl; abst 1119).
20. A Valachis NP Polyzos NA Patsopoulos V Georgoulias D Mavroudis D Mauri 2010 Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials Breast Cancer Res Treat 122 1 1 7 20063120 10.1007/s10549-009-0727-0 1:CAS:528:DC%2BC3cXntlKlsr4%3D This meta-analysis shows that the addition of bevacizumab to chemotherapy offers meaningful improvement in PFS and ORR in MBC patients. No significant advantage was observed in OS with the addition of bevacizumab when pooling phase 3 data
21. IE Smith JY Pierga L Biganzoli H Cortes-Funes C Thomssen X Pivot, et al. 2011 First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients Ann Oncol 22 3 595 602 20819780 10.1093/annonc/mdq430 1:STN:280:DC%2BC3MzivFyjtg%3D%3D This study showed in a real world oncology practice setting and in a very large number of women with metastatic breast cancer that combining bevacizumab with different types of chemotherapy was well tolerated and didn't have greater toxicities than what were reported in the phase 3 trials
22. •• Biganzoli L, Di Vincenzo E, Jiang Z, Lichinitser M, Shen Z, Delva R, et al. First-line bevacizumab-containing therapy for breast cancer: results in patients aged∈>∈=70 years treated in the ATHENA study. Ann Oncol. 2011 Mar 28. This study is the largest study to date evaluating the side effect profile of bevacizumab plus chemotherapy in older women (70 and older) with MBC. It shows that the combination of weekly paclitaxel and bevacizumab appeared to be particularly active in this patient population, with no additional safety signals.
23. FDA begins process to remove breast cancer indication from avastin label [Internet]. U.S. Food and Drug Administration; 2010 [updated 12/16/2010. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ ucm237172.htm.
24. FA Eskens J Verweij 2006 The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review Eur J Cancer 42 18 3127 39 17098419 10.1016/j.ejca.2006.09.015 1:CAS:528:DC%2BD28Xht12rtrzJ (Pubitemid 44869016)
25. X Zhu S Wu WL Dahut CR Parikh 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 2 186 93 17261421 10.1053/j.ajkd.2006.11.039 1:CAS:528:DC%2BD2sXis1Kgu78%3D (Pubitemid 46178407)
26. J Cortes J O'Shaughnessy D Loesch JL Blum LT Vahdat K Petrakova, et al. 2011 Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 377 9769 914 23 21376385 10.1016/S0140-6736(11)60070-6 1:CAS:528:DC%2BC3MXjtFWgs7c%3D
27. Cortes J, Montero AJ, Gluck S. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev. 2011 May 6.
28. ED Saad A Katz PM Hoff M Buyse 2010 Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature Ann Oncol 21 1 7 12 19901012 10.1093/annonc/mdp523 1:STN:280:DC%2BD1MfivFWruw%3D%3D
29. A Di Leo H Bleiberg M Buyse 2003 Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer J Clin Oncol 21 10 2045 7 12743164 10.1200/JCO.2003.99.089
30. Cortazar P, Zhang JJ, Sridhara R, Justice RL, Pazdur R. Relationship between OS and PFS in metastatic breast cancer (MBC): review of FDA submission data. J Clin Oncol. 2011;29(suppl; abstr 1035).
31. AM Jubb AL Harris 2010 Biomarkers to predict the clinical efficacy of bevacizumab in cancer Lancet Oncol 11 12 1172 83 21126687 10.1016/S1470-2045(10) 70232-1 1:CAS:528:DC%2BC3cXhsVyhsLbP
32. BP Schneider M Wang M Radovich GW Sledge S Badve A Thor, et al. 2008 Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 28 4672 8 18824714 10.1200/JCO.2008.16.1612 1:CAS:528:DC%2BD1cXht1KqtLfE
33. BK Linderholm H Hellborg U Johansson G Elmberger L Skoog J Lehtio, et al. 2009 Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer Ann Oncol 20 10 1639 46 19549711 10.1093/annonc/mdp062 1:STN:280:DC%2BD1MnjvFyitQ%3D%3D
34. A Dowlati R Gray AB Sandler JH Schiller DH Johnson 2008 Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an eastern cooperative oncology group study Clin Cancer Res 14 5 1407 12 18316562 10.1158/1078-0432.CCR-07-1154 1:CAS:528:DC%2BD1cXislSrs7c%3D (Pubitemid 351413922)
35. M Ronzoni M Manzoni S Mariucci F Loupakis S Brugnatelli K Bencardino, et al. 2010 Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients Ann Oncol 21 12 2382 9 20497963 10.1093/annonc/mdq261 1:STN:280:DC%2BC3cbotFGqtA%3D%3D
36. SX Yang SM Steinberg D Nguyen TD Wu Z Modrusan SM Swain 2008 Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer Clin Cancer Res 14 18 5893 9 18794102 10.1158/1078-0432.CCR-07-4762 1:CAS:528:DC%2BD1cXhtFaitrjK
37. N Denduluri SX Yang AW Berman D Nguyen DJ Liewehr SM Steinberg, et al. 2008 Circulating biomarkers of bevacizumab activity in patients with breast cancer Cancer Biol Ther 7 1 15 20 18059178 10.4161/cbt.7.1.5337 1:CAS:528:DC%2BD1cXms1OgsrY%3D (Pubitemid 351590445)
38. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 42 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
39. Montero AJ, Gluck S, Lopes Jr GD. The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer. J Clin Oncol. 2011;29(suppl; abstr 6060).
40. KJ Dedes K Matter-Walstra M Schwenkglenks BC Pestalozzi D Fink P Brauchli, et al. 2009 Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation Eur J Cancer 45 8 1397 406 19147344 10.1016/j.ejca.2008.12.016 1:CAS:528:DC%2BD1MXltVClt78%3D
41. AL Caplan 2011 Will evidence ever be sufficient to resolve the challenge of cost containment? J Clin Oncol 29 15 1946 8 21502551 10.1200/JCO.2011.34.7039
42. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 76 18160686 10.1056/NEJMoa072113 1:CAS:528: DC%2BD1cXisVOnsg%3D%3D
43. Miles DW, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol. 2008;26(43s).
44. NJ Robert V Dieras J Glaspy AM Brufsky I Bondarenko ON Lipatov, et al. 2011 RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 10 1252 60 21383283 10.1200/JCO.2010.28.0982 1:CAS:528:DC%2BC3MXntlKlsb8%3D
45. JA O'Shaughnessy AM Brufsky 2008 RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer Clin Breast Cancer 8 4 370 3 18757267 10.3816/CBC.2008.n.045
46. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher, et al. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 4 792 9 15681523 10.1200/JCO.2005.05.098 1:CAS:528: DC%2BD2MXitVKitrk%3D (Pubitemid 46224178)
47. Brufsky A, Bondarenko I, Smirnov V, Hurvitz S, Perez E, Ponomarova O, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res. 2009;69(24).
48. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2542 50 17167137 10.1056/NEJMoa061884 1:CAS:528: DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
49. HI Hurwitz L Fehrenbacher JD Hainsworth W Heim J Berlin E Holmgren, et al. 2005 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 15 3502 8 15908660 10.1200/JCO.2005.10.017 1:CAS:528:DC%2BD2MXlsVyhsrs%3D
50. HS Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey, et al. 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 4733 40 19720927 10.1200/JCO.2008.19.8721 1:CAS:528: DC%2BD1MXhtlGgtbbM
51. B Escudier A Pluzanska P Koralewski A Ravaud S Bracarda C Szczylik, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 9605 2103 11 18156031 10.1016/S0140-6736(07)61904-7 (Pubitemid 350296300)